The specialist cancer drug discovery and development business has reported FYJun2017 results showing a £1.45m swing in profitability and a bottom line of £400k. Sareum ended the period with a significantly enhanced balance sheet. The key event in the period was the inking of a commercial licensing agreement of the Company’s novel Chk1 inhibitor targeting solid cancers (now named SRA737) with Sierra Oncology (NASDAQ:SRRA). Sareum is eligible to 27.5% of up to $328.5 million i
19 Oct 2017
A transformational year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A transformational year
Sareum Holdings plc (SAR:LON) | 31.8 2.7 36.6% | Mkt Cap: 32.3m
- Published:
19 Oct 2017 -
Author:
Derren Nathan -
Pages:
8
The specialist cancer drug discovery and development business has reported FYJun2017 results showing a £1.45m swing in profitability and a bottom line of £400k. Sareum ended the period with a significantly enhanced balance sheet. The key event in the period was the inking of a commercial licensing agreement of the Company’s novel Chk1 inhibitor targeting solid cancers (now named SRA737) with Sierra Oncology (NASDAQ:SRRA). Sareum is eligible to 27.5% of up to $328.5 million i